Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming 2016 BIO Investor Forum being held October 18-19, 2016 at the Westin St. Francis Hotel in San Francisco, California. Ocera’s presentation will take place in the Elizabethan B Room at 8:30 AM Pacific Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
OCRX-G
Contact: Susan Sharpe Ocera Therapeutics, Inc. [email protected] 919-328-1109
